Proceedings of the National Academy of Sciences, Volume 123, Issue 13, March 2026. SignificanceThis study presents S-1117, a pan-IgG protease engineered using Seismic’s IMPACT platform to address the limitations of existing therapies in IgG-mediated diseases. The superior pharmacokinetic profile and the polypharmacology of S-1117, ...
PNAS published a clinical update in Research Highlights on 25 Mar 2026.
The item focuses on Polypharmacology of S-1117, an Fc-fused IgG-selective degrading enzyme, for chronic treatment of autoantibody-mediated diseases.
Review the original article for the full source wording and details.